Welcome to our dedicated page for Cvs Health news (Ticker: CVS), a resource for investors and traders seeking the latest updates and insights on Cvs Health stock.
CVS Health Corporation (CVS) delivers integrated healthcare solutions through its retail pharmacies, pharmacy benefits management (CVS Caremark), and Aetna insurance services. This page provides investors and stakeholders with timely access to official announcements, financial disclosures, and strategic developments shaping the company’s role in the evolving healthcare landscape.
Track breaking updates across CVS Health’s core operations, including earnings reports, regulatory filings, partnership announcements, and service expansions. Our curated news collection simplifies monitoring of material events affecting pharmacy networks, insurance offerings, and digital health initiatives while maintaining compliance with financial disclosure standards.
Discover updates on prescription drug pricing strategies, MinuteClinic expansions, formulary changes through Caremark, and Medicare Advantage plan developments. The repository also covers leadership appointments, sustainability efforts, and community health programs central to CVS Health’s consumer-first mission.
Bookmark this page for streamlined access to CVS Health’s latest corporate communications. Combine these updates with SEC filings and earnings call transcripts available on Stock Titan for comprehensive investment analysis.
CVS Health (NYSE: CVS) will partner with the TrumpRx Fertility program to expand access and lower costs for fertility medications. The company said CVS Specialty Pharmacy will be a core partner and offer specialist pharmacists, claims support, financial-assistance help, and next-day delivery or pickup at 9,000 CVS community pharmacies.
The announcement cites a negotiated price reduction for Gonal-F of 84% as the platform's competitive offering and states the program is expected to be available in January 2026. The company emphasized expedited pharmacy processing for time-sensitive IVF cycles and said drug participation may change before launch.
CVS (NYSE:CVS) announced completion of its acquisition of select Rite Aid and Bartell Drugs assets nationwide on Oct 15, 2025. CVS acquired 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington and 626 prescription files across 15 states, now serving more than 9 million former Rite Aid and Bartell patients.
The company hired more than 3,500 former Rite Aid and Bartell colleagues, completed the final store transfers on Sept 30, 2025, and said the U.S. Bankruptcy Court for the District of New Jersey approved the sales in May. CVS plans targeted investments, local grand-opening events, and continued availability of many local brands.
CVS Health (NYSE: CVS) released the 2025 Rx Report: Community Pharmacy Reimagined on Oct 14, 2025, reporting survey results from >2,200 consumers and >1,060 pharmacists and technicians about the future of community pharmacy.
Key findings: 77% of adults trust local pharmacists, 80% prefer face-to-face care, 75% of pharmacy professionals want expanded roles, and 40% of technicians aspire to become pharmacists. CVS says it opened nearly 100 new community locations in 2025 and operates >b>9,000 community health destinations while launching CostVantage™, a cost-based reimbursement framework with a planned 2026 transition for some government programs.
Aetna (NYSE: CVS) reported that for 2026 over 81% of its Medicare Advantage members are in plans rated 4 stars or higher by CMS, and over 63% are in 4.5-star plans. Key MA contracts and enrollments cited include H5522 (1.3M employer-group members; 4.5 stars, 14-year 4+ streak), H5521 (1.1M individual members; 4.5 stars), H3959 (210k; 4 stars), H2293 (134k; 4 stars), H1609 (132k; 4.5 stars, +0.5 star YoY), and H2663 (128k; 4 stars, 14-year 4+ streak). Ratings are based on CMS data published October 9, 2025; enrollment as of September 2025.
CVS (NYSE: CVS) opened a Workforce Innovation and Talent Center and Community Resource Center in Fort Worth on Oct. 7, 2025, in partnership with Fort Worth Housing Solutions.
The WITC offers no-cost, hands-on training for roles such as pharmacy technicians, customer service associates and call center representatives in a simulated retail environment, with graduates encouraged to apply to CVS. The CRC, supported by Aetna, will offer health education, benefits navigation, computers, teleconferencing and space for community events; health screenings are planned for late 2025.
CVS has invested $232 million+ in affordable housing across Texas, helped create or preserve nearly 14,000 housing units, invested in an 80-unit Babers Manor mixed-income residence, and awarded over $700,000 to local organizations this year.
Aetna (NYSE: CVS) has unveiled its 2026 Medicare Advantage (MA) plans, expanding access to affordable healthcare across 43 states plus Washington, D.C., reaching 57 million Medicare-eligible beneficiaries. The company will maintain $0 monthly premium plans in every service area, accessible to 82% of Medicare-eligible beneficiaries.
Key offerings include $0 copays for Tier 1 drugs, covered vaccines at in-network pharmacies, and essential preventive services. The company is expanding its Special Needs Plans, with Chronic Condition SNPs growing to 18 states and Dual Eligible SNPs expanding to 119 new counties. Members will benefit from a $2,100 annual out-of-pocket maximum for prescription drugs and access to comprehensive networks including major pharmacy chains.
BetterInvesting Magazine has selected Vertiv Holdings Co. (NYSE: VRT) as its "Stock to Study" for the December 2025 issue, highlighting the company's fundamental data including sales, earnings, pre-tax profit, and return on equity for investor analysis.
Additionally, the magazine will feature a fundamental review of CVS Health Corp. (NYSE: CVS), which the Editorial Advisory and Securities Review Committee considers potentially undervalued and worthy of further study. The committee consists of certified financial analysts and is chaired by editor Doron P. Levin.
CVS Health (NYSE: CVS) has scheduled its third quarter 2025 earnings conference call for Wednesday, October 29th, 2025, at 8:00 a.m. ET. During this call, the company will discuss its Q3 2025 financial performance with analysts and investors.
The event will be accessible through an audio webcast on the Investor Relations section of CVS Health's website at investors.cvshealth.com. The webcast recording will remain available for replay on the website for one year following the event.
Omnicare, a subsidiary of CVS Health (NYSE: CVS), has initiated voluntary Chapter 11 bankruptcy proceedings in response to litigation challenges and industry-wide financial pressures. The company has secured $110 million in debtor-in-possession financing to maintain operations during the restructuring process.
The bankruptcy filing follows a court ruling in the U.S. District Court for the Southern District of New York regarding alleged technical violations of pharmacy law. Omnicare plans to use this process to evaluate restructuring options, including a potential standalone restructuring or sale strategy. The company emphasizes that it will continue providing uninterrupted pharmacy services to long-term care facilities and maintain regular business operations, including employee wages and vendor payments.
CVS Health's Aetna (NYSE: CVS) announced the expansion of its Aetna Clinical Collaboration (ACC) program, which will be implemented in ten hospitals by the end of 2025. The program embeds Aetna nurses within hospital staff to support Medicare Advantage members during their hospital discharge and transition process.
The initiative, which has already shown promising results with 25% of program members actively engaged with an Aetna care manager, aims to reduce 30-day readmission rates and hospital length of stay by 5% year-over-year. The program is particularly significant as nearly 20% of Medicare-insured patients face hospital readmission within 30 days of discharge.